Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies

Blood Adv. 2021 Aug 24;5(16):3062-3065. doi: 10.1182/bloodadvances.2021005328.

Authors

Jennifer L Crombie^{1

2}, Amy C Sherman^{1

3}, Chi-An Cheng^{2

4

5}, Christine E Ryan^{1

2}, Rebecca Zon^{1

2}, Michaël Desjardins^{1

3

6}, Peter Baker¹, Mikaela McDonough¹, Natalie Izaguirre^{1

3}, Bruce Bausk³, Jonathan Krauss³, Tal Gilboa^{2

4

5}, Yasmeen Senussi⁴, David R Walt^{2

4

5}, Matthew S Davids^{1

2}, Jennifer R Brown^{1

2}, Philippe Armand^{1

2}, Lindsey R Baden^{1

3}, Nicolas Issa^{1

3}

Affiliations

¹ Dana-Farber Cancer Institute, Boston, MA.
² Harvard Medical School, Boston, MA.
³ Department of Medicine and.
⁴ Department of Pathology, Brigham and Women's Hospital, Boston, MA.
⁵ Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA; and.
⁶ Division of Infectious Diseases, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

No abstract available

Publication types

Comment

MeSH terms

COVID-19 Vaccines
COVID-19*
Humans
Neoplasms*
RNA, Messenger
SARS-CoV-2

Substances

COVID-19 Vaccines
RNA, Messenger

Grants and funding

R01 CA213442/CA/NCI NIH HHS/United States